Enzolytics Inc (OTCMKTS: ENZC), this week, announced hiring Steve Sharabura as its President for subsidiary RobustoMed, Inc. The subsidiary is based out of Atlanta. RobustoMed, Inc. shall kick off a new model for its business that will focus on developing opportunities for the international partnership. This pertains specifically to product companies and medical development stage drug candidates.
Role of new President for subsidiary
Mr. Steve Sharabura is liable for driving the partnership expansion and revenue in the company’s key markets across the world. This includes Costa Rica and Brazil, apart from other markets with a buzz. Mr. Sharabura is a native of Quebec in Canada and is an experienced international affair professional.
In the past, he has also led expansion in the technology sector of a leading United Nations Agency. He had successfully sold emerging technologies worth over $10 million to major telecommunication firms in his previous role. Steve brings 30 years of sales and operational experience in the technological fields. He has experience in a range of large multinational companies and small enterprises. His previous roles included successful improvement in corporate productivity in a range of disciplines.
Mr. Steve Sharabura has a professional degree of Masters in Business Administration and is an alumnus of Cornell University. Additionally, he has a Bachelor of Administrative Science (Economics) degree, and he’s an alumnus of the University of Western Ontario.
CEO statement on the new appointment
The CEO of Enzolytics, Charles Cotropia, stated that adding an experienced professional like Steve Sharabura to the team would add benefits for implementing new business models for the subsidiary, RobustoMed. The company is looking for a growth trajectory in the times to follow. The primary concern of the company at the moment is aggressive growth, the newly appointed President added.
About Enzolytics, Inc.
Enzolytics, Inc. is a drug development company that specializes in multitudes of proprietary therapeutics commercialization.